Juno Therapeutics, Inc. (NASDAQ:JUNO) recorded a trading volume of 2.1 million shares, below its 90-day volume average of 2.21 million shares. The stock kicked off the session at $49 and later approached $50.09 with a change of 2.35%.Juno Therapeutics, Inc. (JUNO) Analyst Opinion
Juno Therapeutics, Inc. has a consensus outperform rating from 15 Wall Street analysts, and the number of shares currently sold short amount to at least 9.85% of shares outstanding. The stock sank -0.3% last month and is up 9.58 this year. Wall Street is only getting more bullish on the stock, with 10 of analysts who cover JUNO having a buy-equivalent rating. Analysts have placed a $55.54 price target on Juno Therapeutics, Inc., suggesting a 10.88% gain from recent close. It’s currently trading about -21.06% below its 52-week high.Juno Therapeutics, Inc. Earnings Surprise
Juno Therapeutics, Inc. (JUNO) surprised the stock market in its last reported earnings when it earned -$0.73 a piece versus the consensus-estimated -$0.86. Its revenue totaled $16.2 million down -23.84% from the previous quarter.Juno Therapeutics, Inc. (NASDAQ:JUNO) Intraday View
This stock (JUNO) is ahead of its 52-week low with 165.03%. Its last month’s stock price volatility remained 4.67% which for the week stands at 5.32%. The share price has moved forward from its 20 days moving average, trading at a distance of 7.7% and stays -3.79% away from its 50 days moving average. Over the last five days, shares have managed 4.99% gains and now is up 37.79% since hitting its 200-day moving average of $41.88. Juno Therapeutics, Inc. (JUNO) has made its way to a 12-month gain of 155.43%.
Turning to AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), its shares were trading at $14.35 a retreat of $-0.4, on the trading floor. The stock, after opening at $14.75, touched a high of $15.15 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.8. AMAG Pharmaceuticals, Inc. has 1 buy ratings, 9 holds and 0 sells even after the stock tumbled -43.06% from its high of $25.20 to a $515.17 million market value through last close.AMAG Pharmaceuticals, Inc. (AMAG) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 2.73 to 2.73 during a month. Analysts set a 12-month price target of $17.64 a share. The target implies a 22.93% spike from where the shares are currently trading. Also, the current price highlights a discount of 53.31% to analysts’ high consensus price target.AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Intraday Trading
The counter witnessed a trading volume of 1.02 million shares versus an average volume of 0.87 million shares during last trading session. Its last month’s stock price volatility remained 5.62% which for the week approaches 4.99%. The lowest price the stock reached in the last trading day was $14.2 and compares with the $11.93 52-week low. The stock recovered 20.34% since its low point and has performed 8.3% year-to-date.